Rezurock™ (belumosudil) Is Available From Onco360!
REZUROCK (belumosudil), a new oral treatment for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Dosage Form and Strength1
Available in 200 mg (NDC 79802-200-30) tablets in 30-count pill bottles.
Dosage and Administration
The recommended dose is 200 mg (1 tablet) orally once daily with food until the progression of chronic GVHD that requires new systemic therapy.
For full prescribing information, visit Rezurock.com
How to Refer
Oncomed Dba Onco360 or
1REZUROCK™ Prescribing Information: Kadmon Pharmaceuticals, LLC accessed 7/21. REZUROCK™ trademark is owned or licensed by Kadmon Pharmaceuticals, LLC.